A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

Inclusion Criteria:

• Subjects must have a documented diagnosis of ulcerative colitis at least 6 monthsprior to screening.

• Subjects must have active moderate-to-severe ulcerative colitis based on Mayo score.

• Subjects must have Modified Baron endoscopic score of at least 2 determined within 7days of first dosing.

• Subjects must have failed or be intolerant (as determined by the investigator) of atleast one of the following treatments for UC: Oral corticosteroids, azathioprine or 6-mercaptopurine (6-MP), or anti-tumor necrosis factor (TNF) therapy, eg, infliximabor adalimumab.

• Subjects must be on stable steroid doses.

Exclusion Criteria:

• Subjects who have abnormal organ and marrow function.

• Subjects with a diagnosis of indeterminate colitis, or clinical findings suggestive ofCrohn's disease.

• Subjects who meet Truelove-Witts criteria for severe ulcerative colitis.

• Subjects receiving or who are expected to receive Infliximab or other biologictreatment within 8 weeks of the Day 1 study visit.

• Subjects receiving or who are expected to receive Cyclosporine, mycophenolate, ortacrolimus within 4 weeks of the Day 1 study visit.